Under construction – not a live service
Sign in
Not yet taking people in FinlandPhase 2

Comparing PSMA and FAP imaging markers in metastatic prostate cancer

Examines PSMA and FAP levels in individual metastases of people with prostate cancer.

Key facts

Who runs it
Turku University Hospital
Where
Turku, FinlandSee the site
Registry title
Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?
Status
Not yet recruiting
Phase
Phase 2
People taking part
40 people, planned
Started
23 Jan 2024
Planned end
31 Dec 2025
Type of study
Interventional
Record updated
28 February 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with prostate cancer that has spread to distant parts of the body. It studies PSMA and FAP on the cancer spots.

Age
50-85 years at baseline
Sex
Men only
Disease stage
Prostate cancer confirmed by tissue examination, with at least one distant metastasis seen on CT, MRI, bone scan or SPECT imaging. WHO performance score 0-2.
Earlier treatment
All previous treatment lines are allowed.

Main reasons for not taking part

  • Cannot understand the purpose of the study
  • Medical conditions that prevent whole-body PET/CT imaging

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Men with histologically confirmed prostate cancer
  • Age 50-85 years at baseline
  • WHO performance score 0-2
  • At least one distant metastasis detected on CT, MRI, bone scintigraphy (BS) or single-photon emission computed tomography (SPECT) imaging
  • All previous treatment lines are allowed
  • Patient signs informed consent form after receiving written information

Who cannot take part

  • Medical conditions prohibiting whole-body PET/CT imaging
  • Patient is not able to understand the purpose of the study

Where in Finland

  • Turku University HospitalTurku, FinlandNot yet recruiting

About the trial

What the trial wants to find out

Evaluate the lesion-specific expression of prostate-specific membrane antigen (PSMA) and fibroblast activation-protein (FAP) in metastatic prostate cancer

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?
Plain-language title
Comparing PSMA and FAP imaging markers in metastatic prostate cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
28 February 2024